The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Prednisolone or Pentoxifylline for Alcoholic Hepatitis
Open accessAbstract
BACKGROUND: Alcoholic hepatitis is a clinical syndrome characterized by jaundice and liver impairment that occurs in patients with a history of heavy and prolonged alcohol use. The short-term mortality among patients with severe disease exceeds 30%. Prednisolone and pentoxifylline are both recommended for the treatment of severe alcoholic hepatitis, but uncertainty about their benefit persists. METHODS: We conducted a multicenter, double-blind, randomized trial with a 2-by-2 factorial design to evaluate the effect of treatment with prednisolone or pentoxifylline. The primary end point was mortality at 28 days. Secondary end points included death or liver transplantation at 90 days and at 1 year. Patients with a clinical diagnosis of alcoholic hepatitis and severe disease were randomly assigned to one of four groups: a group that received a pentoxifylline-matched placebo and a prednisolone-matched placebo, a group that received prednisolone and a pentoxifylline-matched placebo, a group that received pentoxifylline and a prednisolone-matched placebo, or a group that received both prednisolone and pentoxifylline. RESULTS: A total of 1103 patients underwent randomization, and data from 1053 were available for the primary end-point analysis. Mortality at 28 days was 17% (45 of 269 patients) in the placebo-placebo group, 14% (38 of 266 patients) in the prednisolone-placebo group, 19% (50 of 258 patients) in the pentoxifylline-placebo group, and 13% (35 of 260 patients) in the prednisolone-pentoxifylline group. The odds ratio for 28-day mortality with pentoxifylline was 1.07 (95% confidence interval [CI], 0.77 to 1.49; P=0.69), and that with prednisolone was 0.72 (95% CI, 0.52 to 1.01; P=0.06). At 90 days and at 1 year, there were no significant between-group differences. Serious infections occurred in 13% of the patients treated with prednisolone versus 7% of those who did not receive prednisolone (P=0.002). CONCLUSIONS: Pentoxifylline did not improve survival in patients with alcoholic hepatitis. Prednisolone was associated with a reduction in 28-day mortality that did not reach significance and with no improvement in outcomes at 90 days or 1 year. (Funded by the National Institute for Health Research Health Technology Assessment program; STOPAH EudraCT number, 2009-013897-42 , and Current Controlled Trials number, ISRCTN88782125 ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
European Association for the Study of the Liver (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.010 · Cited by 2,925
O'Shea, R. S., Dasarathy, S., & McCullough, A. J. (2010) · Hepatology · doi:10.1002/hep.23258 · Cited by 1,077
Corticosteroid therapy of alcoholic hepatitis
Maddrey, W. C., Boitnott, J. K., Bedine, M. S., Weber, F. L., Mezey, E., & White, R. I. (1978) · Gastroenterology · doi:10.1016/0016-5085(78)90401-8 · Cited by 925
Lucey, M. R., Mathurin, P., & Morgan, T. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0805786 · Cited by 863
Akriviadis, E., Botla, R., Briggs, W., Han, S., Reynolds, T., & Shakil, O. (2000) · Gastroenterology · doi:10.1053/gast.2000.20189 · Cited by 800
Mathurin, P., O'Grady, J., Carithers, R. L., Phillips, M., Louvet, A., Mendenhall, C. L., Ramond, M.-J., Naveau, S., Maddrey, W. C., & Morgan, T. R. (2011) · Gut · doi:10.1136/gut.2010.224097 · Cited by 455
Self-citationGlucocorticoids plus N-Acetylcysteine in Severe Alcoholic Hepatitis
Nguyen-Khac, E., Thevenot, T., Piquet, M.-A., Benferhat, S., Goria, O., Chatelain, D., Tramier, B., Dewaele, F., Ghrib, S., Rudler, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1101214 · Cited by 410
A Randomized Trial of Prednisolone in Patients with Severe Alcoholic Hepatitis
Ramond, M.-J., Poynard, T., Rueff, B., Mathurin, P., Théodore, C., Chaput, J.-C., & Benhamou, J.-P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260802 · Cited by 392
Louvet, A., Wartel, F., Castel, H., Dharancy, S., Hollebecque, A., Canva–Delcambre, V., Deltenre, P., & Mathurin, P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.062 · Cited by 367
Mathurin, P., Duchatelle, V, Ramond, M., Degott, C., Bedossa, P., Erlinger, S., Benhamou, J., Chaput, J., Rueff, B., & Poynard, T. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8964410 · Cited by 292
Mendenhall, C. L., Anderson, S., Garcia-Pont, P., Goldberg, S., Kiernan, T., Seeff, L. B., Sorrell, M., Tamburro, C., Weesner, R., Zetterman, R., et al. (1984) · New England Journal of Medicine · doi:10.1056/nejm198412063112302 · Cited by 267
Mathurin, P., Louvet, A., Duhamel, A., Nahon, P., Carbonell, N., Boursier, J., Anty, R., Diaz, E., Thabut, D., Moirand, R., et al. (2013) · JAMA · doi:10.1001/jama.2013.276300 · Cited by 210
RAMBALDI, A., SACONATO, H. H., CHRISTENSEN, E., THORLUND, K., WETTERSLEV, J., & GLUUD, C. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03685.x · Cited by 206
Pentoxifylline versus prednisolone for severe alcoholic hepatitis: A randomized controlled trial
De, B. K., Gangopadhyay, S., Dutta, D., Baksi, S. D., Pani, A., & Ghosh, P. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1613 · Cited by 154
Determinants of long-term outcome in severe alcoholic hepatitis
Potts, J. R., Goubet, S., Heneghan, M., & Verma, S. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12427 · Cited by 126
Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis
Parker, R., Armstrong, M. J., Corbett, C., Rowe, I., & Houlihan, D. D. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12279 · Cited by 105
Park, S. H., Kim, D. J., Kim, Y. S., Yim, H. J., Tak, W. Y., Lee, H. J., Sohn, J. H., Yoon, K. T., Kim, I. H., Kim, H. S., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.05.014 · Cited by 83
Singal, A. K. (2013) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v4.i2.16 · Cited by 28
Cited by
Seitz, H. K., Bataller, R., Cortez-Pinto, H., Gao, B., Gual, A., Lackner, C., Mathurin, P., Mueller, S., Szabo, G., & Tsukamoto, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0014-7 · Cited by 1,271
EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
Thursz, M., Gual, A., Lackner, C., Mathurin, P., Moreno, C., Spahr, L., Sterneck, M., & Cortez-Pinto, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.018 · Cited by 943
Self-citationCrabb, D. W., Im, G. Y., Szabo, G., Mellinger, J. L., & Lucey, M. R. (2020) · Hepatology · doi:10.1002/hep.30866 · Cited by 922
Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease
Duan, Y., Llorente, C., Lang, S., Brandl, K., Chu, H., Jiang, L., White, R. C., Clarke, T. H., Nguyen, K., Torralba, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1742-x · Cited by 844
ACG Clinical Guideline: Alcoholic Liver Disease
Singal, A. K., Bataller, R., Ahn, J., Kamath, P. S., & Shah, V. H. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.469 · Cited by 835
Metadata
- Authors
- Thursz, M. R., Richardson, P., Allison, M., Austin, A., Bowers, M., Day, C. P., Downs, N., Gleeson, D., MacGilchrist, A., Grant, A., Hood, S., Masson, S., McCune, A., Mellor, J., O’Grady, J., Patch, D., Ratcliffe, I., Roderick, P., Stanton, L., Vergis, N., Wright, M., Ryder, S., & Forrest, E. H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-23
- Volume
- 372
- Issue
- 17
- Pages
- 1619-1628
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973630785
- Cited by
- 769
- References
- 18
- FWCI
- 50.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.